MEK inhibitorPhase 3 trialInvestigational
Selumetinib
How it works
Blocks the MEK enzyme, which is overactive in certain types of leukemia, reducing cancer cell growth.
Cancer types
Leukemia— All patients
Efficacy
In clinical trials, around 40% of patients achieved a complete or partial response, with a median progression-free survival of approximately 4 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.